On this page

Proparacaine Hydrochloride

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Proparacaine Hydrochloride
Generic name
Proparacaine Hydrochloride
Dosage form
Solution/ Drops
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
Sportpharm LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
12
Packages
12
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Proparacaine Hydrochloride 5 mg/mL 1247445 —

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Ophthalmic
Presentations
24

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Local Anesthesia [PE] PE All 53 members
Local Anesthetic [EPC] EPC 1 member — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
040074
Application type
ANDA · Abbreviated New Drug Application
Approval date
September 29, 1995
Sponsor
BAUSCH AND LOMB INC
Products on application
1
Submissions recorded
12
Products approved under application 040074.
Product Trade name Form Strength Ingredient Status TE Flags
040074-001 PROPARACAINE HYDROCHLORIDE SOLUTION/DROPS PROPARACAINE HYDROCHLORIDE Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 040074.
Type No. Action Status Date Review
Supplement 11 Manufacturing (CMC) Approved November 27, 2001 —
Supplement 10 Manufacturing (CMC) Approved March 7, 2001 —
Supplement 9 Manufacturing (CMC) Approved October 5, 2000 —
Supplement 8 Manufacturing (CMC) Approved June 27, 2000 —
Supplement 5 Manufacturing (CMC) Approved May 18, 2000 —
Supplement 7 Manufacturing (CMC) Approved May 15, 2000 —
Supplement 6 Manufacturing (CMC) Approved April 28, 2000 —
Supplement 4 Manufacturing (CMC) Approved June 7, 1999 —
Supplement 3 Manufacturing (CMC) Approved November 19, 1998 —
Supplement 2 Manufacturing (CMC) Approved July 23, 1998 —
Supplement 1 Labeling Approved July 23, 1998 —
Original application 1 Approved September 29, 1995 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260424). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260424 HUMAN PRESCRIPTION DRUG · 20260206 HUMAN PRESCRIPTION DRUG · 20251022 HUMAN PRESCRIPTION DRUG · 20250523

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Proparacaine Hydrochloride Ophthalmic solution is indicated for topical anesthesia in ophthalmic practice. Representative ophthalmic procedures in which the preparation provides good local anesthesia include measurement of intraocular pressure (tonometry), removal of foreign bodies and sutures from the cornea, conjunctival scraping in diagnosis and gonioscopic examination; it is also indicated for use as a topical anesthetic prior to surgical operations such as cataract extraction.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating. Short corneal and conjunctival procedures: 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses. NOTE: Proparacaine hydrochloride ophthalmic solution USP, 0.5% should be clear, colorless to faint yellow color. If the solution becomes darker, discard the solution. FOR TOPICAL OPHTHALMIC USE ONLY

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Proparacaine hydrochloride ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.

WARNINGS NOT FOR INJECTION INTO THE EYE - For topical ophthalmic use only. Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification with accompanying loss of vision. Proparacaine ophthalmic solution is indicated for administration under the direct supervision of a healthcare provider. Proparacaine ophthalmic solution is not intended for patient self-administration.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Pupillary dilation or cycloplegic effects have rarely been observed with proparacaine hydrochloride. The drug appears to be safe for use in patients sensitive to other local anesthetics, but local or systemic sensitivity occasionally occurs. Instillation of proparacaine in the eye at recommended concentration and dosage usually produces little or no initial irritation, stinging, burning, conjunctival redness, lacrimation or increased winking. However, some local irritation and stinging may occur several hours after the instillation. Rarely, a severe, immediate-type, apparently hyperallergic corneal reaction may occur which includes acute, intense and diffuse epithelial keratitis; a gray, ground glass appearance; sloughing of large areas of necrotic epithelium; corneal filaments and, sometimes, iritis with descemetitis. Allergic contact dermatitis with drying and fissuring of the fingertips has been reported. Softening and erosion of the corneal epithelium and conjunctival congestion and hemorrhage have been reported. To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1- 800-417-9175 or FDA at 1-800 -FDA-1088 or www.fda.gov/medwatch

Description

openFDA Drug Labeling

DESCRIPTION Proparacaine hydrochloride ophthalmic solution USP, 0.5% is a local anesthetic for ophthalmic instillation. Each mL of sterile aqueous solution contains active ingredient: proparacaine hydrochloride 5 mg (0.5%) and inactive ingredients: glycerin (tonicity agent), benzalkonium chloride, 0.01% (preservative) and water for injection (vehicle). The pH may be adjusted with hydrochloric acid and/or sodium hydroxide. At the time of manufacture, the air in the container is replaced by nitrogen. Proparacaine hydrochloride is designated chemically as 2-(Diethylamino) ethyl 3-amino-4-propoxybenzoate monohydrochloride. Graphic formula: C 16 H 26 N 2 O 3 •HCl MW 330.85 CAS-5875-06-9 proparacaine-stru

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Proparacaine hydrochloride ophthalmic solution USP, 0.5% is supplied in a low density polyethylene white bottle with a natural dropper tip with a white screw cap in the following size: NDC 70756-193-35 15 mL bottle in carton. Storage: Refrigerate at 2°C to 8° C (36°F to 46°F). Keep bottle tightly closed. Store bottles in carton until empty to protect from light. If solution shows more than a faint yellow color, it should not be used. DO NOT USE IF TAMPER-EVIDENT SEAL IS BROKEN OR MISSING. Keep out of reach of children. Manufactured for: Lifestar Pharma LLC 1200 MacArthur Blvd. Mahwah, NJ 07430 USA Product of Switzerland Revised: July 2024, V-02

Adverse event reports

Source: openFDA FAERS
527
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: PROPARACAINE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II October 2, 2024 Mckesson Medical-Surgical Inc. Corporate Office Temperature abuse: Products exposed to improper temperature above drug label specifications. Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-1923-0 50090-1923 A-S Medication Solutions 1 BOTTLE, DROPPER in 1 CARTON (50090-1923-0) / 15 mL in 1 BOTTLE, DROPPER July 15, 2015
24208-730-06 24208-730 Bausch & Lomb Incorporated 1 BOTTLE, DROPPER in 1 CARTON (24208-730-06) / 15 mL in 1 BOTTLE, DROPPER September 29, 1995
70756-193-35 70756-193 Lifestar Pharma LLC 1 BOTTLE, DROPPER in 1 CARTON (70756-193-35) / 15 mL in 1 BOTTLE, DROPPER May 21, 2025
42571-497-57 42571-497 Micro Labs Limited 1 BOTTLE in 1 CARTON (42571-497-57) / 15 mL in 1 BOTTLE February 1, 2026
68071-4368-5 68071-4368 NuCare Pharmaceuticals,Inc. 15 mL in 1 BOX (68071-4368-5) March 30, 2018
68071-5139-5 68071-5139 NuCare Pharmaceuticals,Inc. 15 mL in 1 BOTTLE (68071-5139-5) December 23, 2019
70518-3408-0 70518-3408 REMEDYREPACK INC. 1 BOTTLE in 1 CARTON (70518-3408-0) / 15 mL in 1 BOTTLE April 8, 2022
61314-016-01 61314-016 Sandoz Inc. 1 BOTTLE in 1 CARTON (61314-016-01) / 15 mL in 1 BOTTLE June 5, 2000
70069-601-01 70069-601 Somerset Therapeutics, LLC 1 BOTTLE in 1 CARTON (70069-601-01) / 15 mL in 1 BOTTLE October 10, 2024
85766-039-15 85766-039 Sportpharm LLC 1 BOTTLE in 1 CARTON (85766-039-15) / 15 mL in 1 BOTTLE August 7, 2025
85766-056-15 85766-056 Sportpharm LLC 1 BOTTLE in 1 CARTON (85766-056-15) / 15 mL in 1 BOTTLE August 22, 2025
85766-057-15 85766-057 Sportpharm LLC 1 BOTTLE, DROPPER in 1 CARTON (85766-057-15) / 15 mL in 1 BOTTLE, DROPPER August 22, 2025
50090-1923 50090-1923 A-S Medication Solutions — September 29, 1995
24208-730 24208-730 Bausch & Lomb Incorporated — September 29, 1995
70756-193 70756-193 Lifestar Pharma LLC — May 21, 2025
42571-497 42571-497 Micro Labs Limited — February 1, 2026
68071-4368 68071-4368 NuCare Pharmaceuticals,Inc. — September 29, 1995
68071-5139 68071-5139 NuCare Pharmaceuticals,Inc. — October 19, 1973
70518-3408 70518-3408 REMEDYREPACK INC. — April 8, 2022
61314-016 61314-016 Sandoz Inc. — June 5, 2000
70069-601 70069-601 Somerset Therapeutics, LLC — October 10, 2024
85766-039 85766-039 Sportpharm LLC — October 10, 2024
85766-056 85766-056 Sportpharm LLC — June 5, 2000
85766-057 85766-057 Sportpharm LLC — September 29, 1995

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 12 sections on this page.